Financial Data and Key Metrics Changes - Kirby Corporation reported a record year in 2025, with over $400 million in free cash flow and a strong balance sheet, having paid down $130 million in debt [4][20] - The company generated cash flow from operations of $670 million for the year, driven by higher revenues and earnings [21] - Total available liquidity at the end of the fourth quarter was approximately $542 million [21] Business Line Data and Key Metrics Changes - Marine transportation segment revenues were $482 million in Q4 2025, with an operating income of $100 million and an operating margin in the low 20% range [10] - Inland marine revenues decreased 1% compared to Q4 2024, primarily due to lower utilization, while coastal revenues increased 22% year-over-year [11][13] - Distribution and services segment revenues were $370 million, with operating income of $30 million and an operating margin of 8.1% [15] Market Data and Key Metrics Changes - Inland barge utilization averaged in the mid- to high-80% range, improving towards the end of the quarter, while coastal barge utilization remained strong in the mid- to high-90% range [6][14] - Power generation revenues grew 47% year-over-year, driven by strong order flow and project wins [7][16] - The oil and gas market continued to face softness, with revenues down 45% year-over-year [18] Company Strategy and Development Direction - Kirby Corporation aims for steady growth and solid performance in 2026, with expectations of improving market conditions and operational momentum [4][9] - The company is focused on a balanced capital allocation approach, returning capital to shareholders while pursuing long-term investment opportunities [22][23] - Power generation is identified as a core growth area, with an expanding backlog and strong customer demand [24][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the refining industry and potential demand from Venezuelan crude, which could positively impact operations [24][37] - The company anticipates stable refinery activity and improving inland utilization, with spot rates showing early signs of an upward trend [8][25] - Despite expected seasonal challenges in Q1, management expects operating performance to strengthen throughout the year [26][28] Other Important Information - The company experienced an increase in medical costs, which is expected to continue in 2026, impacting operating margins [18][19] - Capital expenditures for 2025 totaled $264 million, with expectations for 2026 to fall within the $220 million-$260 million range [22] Q&A Session Summary Question: Inquiry on Q4 term contract pricing and demand outlook - Management noted that the slight decline in term pricing was due to weak demand in Q4, but they have seen spot prices rebound in January, indicating a more positive outlook for 2026 [31][32][36] Question: Clarification on coastal revenue expectations and shipyard impacts - Management confirmed that increased shipyard activity would impact margins, but revenue growth would primarily come from price increases rather than volume [39][40] Question: Discussion on EPS guidance range and underlying factors - Management explained that the broad EPS guidance range is influenced by power generation delivery timing and the potential for improved inland pricing throughout the year [48][49] Question: Update on CapEx guidance and new build pricing - Management indicated that new build pricing remains consistent, with labor costs still high, and they do not anticipate significant acquisitions impacting CapEx guidance [84][87]

Las Vegas Sands (NYSE:LVS) Q4 2025 Earnings call January 28, 2026 04:30 PM ET Company ParticipantsDaniel Briggs - SVP of Investor RelationsDaniel Politzer - Executive Director of Equity ResearchDavid Katz - Managing DirectorGrant Chum - CEO and PresidentJohn DeCree - Head of Equity ResearchPatrick Dumont - President and COORob Goldstein - Chairman and CEORobin Farley - Managing DirectorStephen Grambling - Head of US Gaming, Lodging, and Leisure ResearchSteven Wieczynski - Managing DirectorConference Call Pa ...

Financial Data and Key Metrics Changes - Marina Bay Sands achieved an EBITDA of $806 million, marking the highest quarter in the history of casino hotels, with a total EBITDA exceeding $2.9 billion for the year [5] - Macau delivered an EBITDA of $608 million for the quarter, with an adjusted EBITDA margin of 28.9%, down 390 basis points compared to Q4 2024 [8][9] - The mass gaming revenue in Singapore exceeded $951 million, up 118% from Q4 2019 and up 27% from Q4 last year [5] Business Line Data and Key Metrics Changes - In Singapore, Marina Bay Sands had an EBITDA margin of 50.3%, with a potential EBITDA reduction of $45 million if the rolling program had held as expected [9] - Macau's mass market revenue share exceeded 25%, with a focus on premium segments driving growth [7] - The Venetian's EBITDA margin was reported at 32.3%, while The Londoner's margin was 28.8% [8] Market Data and Key Metrics Changes - The Macau market is currently driven by the premium segment, with a noted increase in rolling business as a proportion of total gaming [19] - The promotional environment in Macau has become more competitive, particularly in the premium segments [31][33] - Property visitation across Sands China exceeded 2019 levels, approaching 100 million visitations in 2025 [103] Company Strategy and Development Direction - The company is focused on delivering revenue and cash flow growth across its portfolio, leveraging scale and product advantages [8] - Continued investment in Singapore and renovations are planned to enhance service models and customer experience [17] - The company is exploring new development opportunities in markets like Japan but is currently focused on existing properties [61] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory in Singapore, citing a strong customer base and high-quality offerings [15][46] - In Macau, management acknowledged challenges in the base mass segment but noted improvements in premium segments and overall market positioning [25][90] - The company aims to maintain a low 30% margin business model while focusing on revenue growth and long-term health [96] Other Important Information - The company repurchased $500 million of LVS stock during the quarter and paid a recurring quarterly dividend of $0.25 per share [9] - The company increased its ownership percentage of SCL to 74.8% as of December 31, 2025 [10] - Rob Goldstein will serve as a senior advisor to the company for the next two years after his tenure as CEO [108] Q&A Session Summary Question: What is driving the strong quarter in Singapore? - Management attributed the success to the property's offerings and an increase in customer visits, with no significant changes needed in operations [15][16] Question: What is the outlook for Macau's EBITDA margins? - Management indicated that margins are expected to be in the low 30% range, influenced by the mix of play and promotional activities [96] Question: How is the promotional environment in Macau evolving? - The promotional environment has become more competitive, particularly in premium segments, but management sees stabilization in the current quarter [31][33] Question: Are there any impacts from the NBA activities on operating expenses? - Higher event costs were noted due to the NBA activities, which were successful but did impact margins [71][72] Question: What is the strategy for the base mass segment in Macau? - Management acknowledged the stagnant growth in the base mass segment but is focusing on leveraging assets and enhancing customer engagement to stimulate higher spending [105][106]

Austin, Texas--(Newsfile Corp. - January 28, 2026) - Bombyll is pleased to announce that Tiffany Gonzalez, Founder of Bombyll will be speaking at TechCon Southwest 2026. This year’s event will be held Feb. 12-13 at the Bullock Museum in Austin, Texas.TechCon Southwest, produced by TechCon Global, is a leading technology and innovation event that brings together investors, founders, thought leaders, and industry experts. The 2026 program features keynotes, panel discussions, fireside discussions, and demos ...

Meta beating on the top and bottom line. EPS of $8.88% versus estimates of $823. Revenues of 59.89% billion showing 24% revenue growth.That's actually an acceleration from the third quarter pace of growth. Analysts had been expecting it to dip slightly um and coming in ahead of estimates of 58.59% billion. The key number here is capex, the company guiding to capex for uh the full year of 2026 in a range of 115 to 135 billion.That is ahead of estimates of about 110 billion. They say this year-over-year growt ...

Core Insights - Danaher Corporation's (DHR) fourth-quarter 2025 adjusted earnings were $2.23 per share, exceeding the Zacks Consensus Estimate of $2.22, marking a 4% year-over-year increase [1] - The company reported net sales of $6.84 billion, surpassing the consensus estimate of $6.79 billion, with a year-over-year growth of 4.5% driven by strong performance across all segments [1] Financial Performance - DHR's core sales increased by 2.5% year over year in the quarter, with foreign-currency translations positively impacting sales by 2.5%, while acquisitions/divestitures had a negative impact of 0.5% [2] - For the full year 2025, DHR reported net revenues of $24.6 billion, a 3% increase year over year, and adjusted earnings of $7.80 per share, up 4.5% year over year [2] Segment Analysis - Life Sciences segment revenues reached $2.09 billion, up 2.5% year over year, exceeding the Zacks Consensus Estimate of $2.06 billion, with core sales increasing by 0.5% [3] - Diagnostics segment revenues totaled $2.72 billion, a 3% year-over-year increase, also surpassing the consensus estimate of $2.71 billion, with operating profit rising 14.3% year over year to $713 million [4] - Biotechnology segment revenues were $2.03 billion, up 9% year over year, exceeding the consensus estimate of $2.02 billion, with core sales increasing by 6% [5] Margin and Cost Structure - In Q4, Danaher's cost of sales increased by 8.5% year over year to $2.87 billion, while gross profit rose by 2% to $3.97 billion, resulting in a gross margin of 59.1%, slightly down from 59.5% in the previous year [6] - Operating profit increased by 5.4% year over year to $1.50 billion, although the operating margin declined to 19.1% from 20.4% in the year-ago quarter [7] Balance Sheet and Cash Flow - At the end of Q4, DHR had cash and equivalents of $4.62 billion, up from $2.08 billion at the end of 2024, while long-term debt increased to $18.4 billion from $15.5 billion [8] - The company generated net cash of $6.42 billion from operating activities in 2025, down from $6.69 billion in the previous year, with capital expenditures totaling $1.16 billion, a 17% decrease year over year [9] Future Outlook - For Q1 2026, Danaher expects low single-digit core sales growth year over year and anticipates adjusted earnings of $8.35-$8.50 per share [10][12] - The company projects a 3-6% increase in adjusted core sales for the full year 2026 [12]

Core Insights - PPG Industries reported a fourth-quarter 2025 profit of $302 million or $1.34 per share, a significant increase from $2 million or a penny per share a year ago, but adjusted earnings per share of $1.51 fell short of the Zacks Consensus Estimate of $1.57 [1][9] - The company's revenues reached $3,914 million, reflecting a 5% year-over-year increase and surpassing the Zacks Consensus Estimate of $3,744.6 million [2][9] Segment Review - The Global Architectural Coatings segment experienced an 8% year-over-year sales increase to $951 million, exceeding estimates due to higher selling prices and favorable foreign currency translation, partially offset by the divestiture of the architectural coatings business in Russia [3] - The Performance Coatings segment saw a 5% year-over-year sales rise to $1,322 million, driven by higher selling prices and favorable currency impacts, despite reduced sales volumes; organic sales grew 3% year over year [4] - The Industrial Coatings segment's sales grew 3% year-over-year to $1,641 million, benefiting from foreign currency translation gains and improved volumes, surpassing estimates [5] Financials - As of the end of the quarter, PPG had $2,163 million in cash and cash equivalents, a 70% increase year over year; long-term debt rose to $6.6 billion, up 35% from the prior-year quarter [6] Outlook - PPG anticipates adjusted earnings per share of $7.70 to $8.10 for full-year 2026, citing ongoing soft global industrial production and mixed regional demand; organic sales are expected to show flat to low single-digit percentage growth [7][9] Price Performance - PPG shares have declined by 11.7% over the past year, contrasting with a 0.4% rise in its industry [8]

Core Insights - Texas Instruments (TXN) reported Q4 2025 earnings per share (EPS) of $1.27, missing the Zacks Consensus Estimate by 2.3% but exceeding the midpoint of management's guidance of $1.13 to $1.39. The EPS decreased by 2% year over year [1][8] - The company generated revenues of $4.42 billion, which was 0.3% below the Zacks Consensus Estimate but above the midpoint of management's guidance of $4.22-$4.58 billion, reflecting a 10% year-over-year increase [2][8] Revenue Breakdown - Texas Instruments operates in three segments: Analog, Embedded Processing, and Other - Analog segment revenues were $3.62 billion, accounting for 81.7% of total revenues, up 14% year over year and above the model estimate of $3.53 billion [3] - Embedded Processing revenues reached $662 million, representing 15% of total revenues, an 8% increase year over year, surpassing the model estimate of $618.7 million [3] - Other segment revenues totaled $146 million, making up 3.3% of total revenues, down 34% year over year and missing the model estimate of $276.1 million [4] Operating Performance - Gross profit increased by 7% year over year to $2.47 billion, with a gross margin of 55.9%, which contracted by 190 basis points year over year [5] - Selling, general and administrative (SG&A) expenses remained flat at $446 million year over year, with SG&A as a percentage of revenues contracting by 100 basis points to 10.1% [5] - Research and development expenses grew by 6.1% to $521 million, decreasing as a percentage of revenues by 160 basis points to 11.8% [5] - Operating profit rose by 7% year over year to $1.47 billion, with an operating margin of 33.3%, which contracted by 110 basis points from the prior year [6] Balance Sheet and Cash Flow - As of December 31, 2025, cash and short-term investments were $4.88 billion, down from $5.19 billion as of September 30, 2025 [7] - Long-term debt was $13.548 billion, a slight increase from $13.546 billion in the previous quarter [7] - Operating cash flow for Q4 was approximately $2.25 billion, with $403 million spent on stock repurchases and $1.29 billion paid in dividends [7][9] Guidance for Q1 2026 - Texas Instruments expects Q1 2026 revenues to be between $4.32 billion and $4.68 billion, with the Zacks Consensus Estimate currently at $4.39 billion, indicating a 7.9% increase year over year [10] - The company anticipates EPS in the range of $1.22 to $1.48, with the consensus mark at $1.30 per share, suggesting a 1.6% year-over-year increase [10]

We came across a bullish thesis on XPEL, Inc. on Capital Light’s Substack by Luke Wolgram. In this article, we will summarize the bulls’ thesis on XPEL. XPEL, Inc.'s share was trading at $53.49 as of January 26th. XPEL’s trailing P/E was 31.46  according to Yahoo Finance. Largest Automotive Companies and Suppliers in the World Photo by Yannis Zaugg on Unsplash XPEL, Inc. manufactures, installs, sells, and distributes protective films, coatings and related services. XPEL has transitioned from a pure grow ...

Financial Data and Key Metrics Changes - For the full year 2025, sales reached $24.6 billion, with core revenue increasing by 2% [9] - Adjusted operating profit margin was 28.2%, and adjusted diluted net earnings per share were $7.80, up 4.5% year-over-year [9] - Free cash flow generated was $5.3 billion, resulting in a free cash flow to net income conversion ratio of approximately 145% [10] Business Line Data and Key Metrics Changes - Biotechnology segment core revenue increased by 6% [16] - Bioprocessing core revenue grew high single digits, with consumables and equipment both contributing to growth [16] - Life sciences segment core revenue increased by 0.5%, with consumables experiencing a decline due to lower demand [19] - Diagnostics segment core revenue increased by 2%, with clinical diagnostics growing mid-single digits [20] Market Data and Key Metrics Changes - Core revenues in developed markets increased low single digits, with North America flat and Western Europe up mid-single digits [15] - High growth markets saw mid-single digit increases, with solid growth outside of China, offsetting a low single-digit decline in China [15] Company Strategy and Development Direction - The company aims for long-term value creation through a differentiated portfolio and the Danaher Business System [9] - Continued investment in innovation led to over 20 new product launches in biotechnology, enhancing customer capabilities [10] - The company anticipates high single-digit core revenue growth in bioprocessing for 2026, driven by strong demand for monoclonal antibodies [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about gradual end market improvements continuing into 2026, supported by a strong balance sheet [9] - The company expects core revenue growth in the range of 3%-6% for 2026, with adjusted diluted EPS guidance set at $8.35-$8.50 [23] - Management noted that the bioprocessing market is expected to grow due to robust FDA approvals and increased uptake of existing therapies [18] Other Important Information - The company has maintained a free cash flow to net income conversion ratio exceeding 100% for 34 consecutive years [10] - The company is well-positioned for M&A opportunities, with a constructive environment and strong cash flow generation [68] Q&A Session Summary Question: Can you discuss the core revenue guidance and potential upside? - Management indicated that the 3%-6% core revenue guidance reflects expectations of continued recovery in end markets, with bioprocessing expected to remain strong [31][34] Question: What is the outlook for bioprocessing and equipment orders? - The order book supports high single-digit growth for bioprocessing, with equipment orders showing sequential growth, although still below historical levels [36] Question: How is the M&A environment shaping up? - The M&A environment is seen as more constructive, with improving valuations and a strong balance sheet allowing for potential aggressive moves [68][70] Question: What are the expectations for life sciences and academic demand? - Management expects gradual improvement in life sciences, particularly in pharma, but noted that academic demand remains muted [84][85] Question: Can you elaborate on the performance of the SCIEX segment? - SCIEX experienced mid-single-digit growth, driven by innovation and improvement in the pharma end market [42][43]